arrow
T

Thomas Aparicio

assistance publique-hôpitaux de paris
H指数:55
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predicting severe toxicities and mortality in older patients with colorectal cancer: An analysis of 3 clinical trials and 3 prospective cohorts.

预测老年结直肠癌患者严重毒性和死亡率:3项临床试验和3项前瞻性队列分析

2026-07-120
OA
FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma

FRUQUITAS试验:三氟尿idine/替匹拉西布联合/不联合 fruquintinib治疗经治转移性胃食管腺癌的ENGIC协作组随机III期研究设计

2026-05-090
OAAI
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: a retrospective study by AGEO

靶向疗法治疗转移性小肠腺癌的疗效:AGEO进行的一项回顾性研究

2026-03-280
PRE
Association between induced organ atrophy assessed by artificial intelligence-generated automatic segmentation and efficacy of bevacizumab in combination with chemotherapy in metastatic colorectal cancer

人工智能自动分割评估的诱导性器官萎缩与贝伐珠单抗联合化疗在转移性结直肠癌中的疗效关联

2025-11-180
OAAI
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: an individual patient data meta-analysis

可切除或已切除结直肠癌肝转移患者的系统性化疗:一项个体患者数据Meta分析

2025-11-010
PRE
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA phase II randomized trial

FOLFIRINOX或FOLFOX用于局部晚期或转移性小肠腺癌:PRODIGE 86 – FFCD-GONO – ENGIC 02 – FOLFIRINOX SBA II期随机试验

2025-07-280
OAAI
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)

基于贝伐珠单抗的化疗,根据贝伐珠单抗药代动力学适应性调整,用于不可切除性转移性结直肠癌患者的一线治疗:一项双盲、多中心、随机III期临床试验研究(PHARBEVACOL试验)

2025-05-010
OAAI
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

循环肿瘤DNA强烈预测化疗联合免疫检查点抑制剂在晚期胃食管腺癌患者中的疗效

2025-04-240
OA
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
2025-03-010
PRE
PRODIGE 86 (FFCD 2103-GONO) - FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma

PRODIGE 86 (FFCD 2103-GONO) - FOLFIRINOX SBA:一项II期随机试验,旨在评估mFOLFIRINOX和mFOLFOX方案在局部晚期或转移性小肠腺癌治疗中的效果。

2024-09-010
PRE
Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34-FFCD 1402-ADAGE randomized phase III trial

PRODIGE 34-FFCD 1402-ADAGE 随机III期试验中,III期结肠腺癌切除术后老年患者辅助化疗的耐受性

2024-09-010
PRE
Trifluridine/tipiracil plus oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial
2024-08-010
OAAI
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases
2024-05-142
PRE